吉西他滨联合顺铂治疗蒽环类及紫杉类耐药的转移性三阴乳腺癌临床观察  

Gemcitabine combined with cisplatin in the treatment of anthracycline and taxane-resistant triple-negative metastatic breast cancer

作　　者：陈彦帆[1] 韦燕[1] 龚建忠[1] 赵善琳[1] 张芸[1] 宁春玉[1] 

机构地区：[1]贵港市人民医院肿瘤科,广西贵港537100

出　　处：《现代肿瘤医学》2010年第10期1977-1979,共3页Journal of Modern Oncology

摘　　要：目的:观察吉西他滨联合顺铂治疗蒽环类及紫杉类耐药的转移性三阴乳腺癌的疗效、影响因素和不良反应。方法:采用吉西他滨联合顺铂治疗蒽环类及紫杉类耐药的转移性三阴乳腺癌28例。吉西他滨1000mg/m2静脉滴注,第1、8天;顺铂80mg/m2,分3天静脉滴注,第1-3天。化疗以21天为1个周期,至少应用2个周期。结果:本组患者治疗有效率为46.4%,中位疾病进展时间为5.5个月。合并有肝脏转移者化疗效果差。无化疗相关死亡病例,主要不良反应为骨髓抑制及胃肠道反应,Ⅲ-Ⅳ级白细胞和血小板下降分别为10.4%和7.1%。结论:吉西他滨联合顺铂方案对蒽环类及紫杉类均耐药的转移性三阴乳腺癌仍有较好的近期疗效,不良反应可耐受,是有效的援救方案。Objective：To investigate the efficacy,influencing factor and toxicity of GP（gemcitabine combined cisplatin）regimen as chemotherapy for anthracycline-and taxane-resistant metastatic triple-negative breast cancer（TNBC）.Methods：Twengty eight patients were treated by GP regimen.All had failures or relapse after previous treatment with anthracyclines and taxanes.GP：1000mg/m2 gemcitabine on d1,8,and DDP 80mg/m2 infusion on d1-3.Treatment was repeated every 21 days and all patients received at least 2 cycles of chemotherapy.Results：The overall response rate（RR）,median time to progression（TTP） was 46% and 5.5 months.No patients died correlated with the GP regimen.Myelosuppression and gastrointestinal tract reaction were the most common toxicities,Grade Ⅲ-Ⅳ leucopenia and thrombocytopenia were 10.4% and 7.1%.Conclusion：GP regimen is effective for patients with anthracycline and taxane-resistant TNBC.Drug-related toxicities are tolerable.GP regimen can be considered as salvage regimen effectively for those patients.

关 键 词：乳腺癌 转移 吉西他滨 顺铂 

分 类 号：R737.9[医药卫生—肿瘤]